Bandage containing foetal fibroblasts and keratinocytes
The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).
1. A composition for accelerating healing of a skin defect comprising a mixture of foetal human keratinocyte cells and foetal human fibroblastic cells in a skin healing accelerating ratio between said keratinocyte and fibroblast cells ranging from 1:1 to 2.5:1.
2. The composition according to claim 1 , wherein said ratio is 1:1 or 7:3.
3. The composition according to claim 1 , wherein said mixture of cells is integrated in a non-immunogenic extracellular matrix.
4. The composition according to claim 3 , wherein said mixture of cells is present in a concentration consisting of between 0.1×10 6 and 5×10 6 cells per cm 3 of matrix.
5. The composition according to claim 3 wherein said matrix contains at least one compound selected from the group consisting of collagen, fibronectin, fibrin, and elastin, and mixtures thereof.
6. The composition according to claim 3 , wherein said matrix is composed of human fibrinogen, human factor XIII, human fibronectin, plasminogen, bovine aprotinin and human thrombin.
7. A bandage containing a composition which comprises a mixture of foetal human keratinocyte cells and foetal human fibroblastic cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5.
8. The bandage according to claim 7 , wherein said bandage is sterile and packaged in a container impermeable to microorganisms.
9. A method for treating a skin defect in a patient in need thereof, comprising the step of administering to said patient a composition which comprises a mixture of foetal human keratinocyte cells and foetal human fibroblastic cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5.
10. A process for manufacturing a composition comprising the step of mixing foetal human keratinocyte cells and foetal human fibroblastic cells with a non-immunogenic extracellular matrix, in a ratio ranging from 0.75 to 2.5.
11. The manufacturing process according to claim 10 , wherein said ratio is 1:1 or 7:3.
12. The manufacturing process according to claim 10 comprising, prior to said mixing step, the following two steps:
a) obtaining foetal human keratinocyte cells, and
b) obtaining foetal human fibroblastic cells.
13. The manufacturing process according to claim 10 comprising, prior to the mixing step, the following two steps:
a) obtaining a bank of foetal human keratinocyte cells, and
b) obtaining a bank of foetal human fibroblastic cells.
14. The bandage according to claim 7 wherein said ratio is 1:1 or 7:3.
15. The method according to claim 9 wherein the skin defect is a wound, a burn or an ulcer.
16. The method according to claim 9 wherein said ratio is 1:1 or 7:3.
17. The composition according to claim 1 , wherein the skin defect is a wound, a burn or an ulcer.